1.Preliminary analysis on genetic variation of Iphigenia indica by RAPD
Chinese Traditional and Herbal Drugs 1994;0(06):-
Object To study on the genetic diversity and genetic structure of Iphigenia indica Kunth. Methods Random amplified polymorphic DNA (RAPD) was applied to detect DNA fingerprints of three populations of I. indicafrom Yunnan Province. Results Twenty primers were screened, and a total of 120 DNA fragments were amplified ranging from 0.2-3 kb, among which 71 (59.17%) were polymorphic. The average number of DNA band produced by each primer was 3.55. The Shannon index was (0.199 4) in Ca population, 0.200 7 in Cb population, 0.254 8 in Cc population, respectively; the average value of populations was 0.218 3. The Shannon index was 0.288 6 in species. Nei's genetic identity was 0.930 9 between Ca and Cb, 0.932 7 between Ca and Cc, 0.946 6 between Cb and Cc. G_(st) within population was (0.204 4.) Conclusion For the establishment of protective tactic and measure, and of the standard of good agriculture practice (GAP) growth and heredity breeding, RAPD analysis provides I. indicawith theoretical foundation and basal data.
2.Development and management of the information management system of metabolic disorder biobanks
Chinese Journal of Medical Science Research Management 2013;(3):204-206,209
Metabolic diseases information consulting provides its clients with data and insight to help translation information medicine product development plans:for clinical,diagnosis,biologics,medical devices/combination products.Understanding the mechanisms by which specific protein functions contribute to metabolic disease pathogenesis is a great challenge.The barcode is the common nominator and identifier of a sample.This code can be utilized in both 2D form,capturing important identifiers for each sample type and origin.Visual database informational system,to impact on the quality of the analysis data generated.Our ultimate motivation lies in helping you to advance the translation medicine success of our hospital,and to optimize the benefit they provide to patients in need.
3.Lead compound optimization strategy (4)--improving blood-brain barrier permeability through structural modification.
Yu HONG ; Yu ZHOU ; Jiang WANG ; Hong LIU
Acta Pharmaceutica Sinica 2014;49(6):789-799
Blood-brain barrier is a natural protection for human body. It protects central nervous system from the interruption and damage of xenobiotics. However, it prevents potential drugs aimed at central nervous system, thus becomes an obstruction for the development of central nervous system drugs. The recent development of blood-brain barrier permeability research and several lead optimization strategies to improve blood-brain barrier permeability are reviewed. These structure optimization methods include increasing lipophilicity, reducing hydrogen bond doners, simplifying molecule, increasing rigidity, lowering polar surface area, avoiding acid group, prodrug strategy, modifying into active transporter's substrates, as well as avoiding P-glycoprotein recognized structures.
ATP-Binding Cassette, Sub-Family B, Member 1
;
metabolism
;
Biological Transport
;
Blood-Brain Barrier
;
Central Nervous System
;
drug effects
;
Central Nervous System Agents
;
pharmacokinetics
;
Drug Design
;
Humans
;
Permeability
;
Xenobiotics
;
adverse effects
4.Lead compound optimization strategy (4)--improving blood-brain barrier permeability through structural modification.
Yu HONG ; Yu ZHOU ; Jiang WANG ; Hong LIU
Acta Pharmaceutica Sinica 2014;49(6):789-99
Blood-brain barrier is a natural protection for human body. It protects central nervous system from the interruption and damage of xenobiotics. However, it prevents potential drugs aimed at central nervous system, thus becomes an obstruction for the development of central nervous system drugs. The recent development of blood-brain barrier permeability research and several lead optimization strategies to improve blood-brain barrier permeability are reviewed. These structure optimization methods include increasing lipophilicity, reducing hydrogen bond doners, simplifying molecule, increasing rigidity, lowering polar surface area, avoiding acid group, prodrug strategy, modifying into active transporter's substrates, as well as avoiding P-glycoprotein recognized structures.
5.Effect of methazolamide in patients with refractory uveitic macular edema
Yun-Bin, JIANG ; Hong, ZHU ; Yu-Hong, CHEN ; Hong, WANG
International Eye Science 2017;17(7):1359-1361
AIM:To evaluate the efficacy and safety of methazolamide in treating refractory uveitic macular edema.METHODS: Retrospective self-controlled study was designed.A total of 15 patients (20 eyes) with refractory uveitic macular edema which used methazolamide as adjuvant therapy were enrolled in Shanghai First People`s Hospital from January 2015 to June 2016.The changes of central macular thickness (CMT) and best corrected visual acuity (BCVA) were observed at baseline and 2, 4, 8wk after treatment.We also focused on the incidence of complications and relapse.RESULTS: The CMT was 445.95±154.10μm, 338.83±138.34μm, 251.50±40.20μm, 244.90±35.68μm at baseline, 2, 4 and 8wk after treatment, respectively.The differences among them were statistically significant (F=15.467, P<0.05).The BCVA (log MAR) were 0.40±0.17, 0.28±0.21, 0.19±0.20, 0.18±0.21 at baseline, 2, 4 and 8wk respectively, with a significant difference among them (F=5.208, P<0.05).When the cumulative dose reached to 700mg and 1400mg, no one had methazolamide-related complications;and when it came to 2800mg, 5 patients (33%) had methazolamide-related complication.After the withdrawal of methazolamide 1wk, 1 and 3mo, 3 patients (20%), 5 patients (33%) and 8 patients (53%) relapsed, respectively.CONCLUSION: Methazolamide is beneficial in improving macular edema and vision in 4wk.When the cumulative dose is more than 1400mg, we need pay attention to the complications.After discontinuing methazolamide for 1wk, macular edema relapsed in some patients, and more than half of patients recurred after 3mo.So the patients should be followed closely in 3mo after withdrawal of methazolamide.
7.Evaluation on clinical efficacy of hyperbaric oxygenation in treatment of sudden deafness :A Meta-analysis
Ranyang MA ; Hong YU ; Xin WANG
Journal of Jilin University(Medicine Edition) 2017;43(2):298-305
Objective:To evaluate the clinical efficacy of treatment of sudden deafness using hyperbaric oxygenation, and to provide guidance for its treatment. Methods:The studies about sudden deafness treated with hyperbaric oxygenation combined with drug were retrieved in Cochrane Library, PubMed , MEDLINE, Wanfang Database and CNKI up to July 2016.RavMan 5.3 provided by Cochrane was used for Meta-analysis.Results:Thirty-nine studies which were randomized controlled trials (RCTs)were included, a total of 4 599 cases,of which 2 418 cases received hyperbaric oxygenation therapy combined with drug treatment as treatment group and 2 181 cases received drug treatment alone as control group.A total of 36 studies about the comparison of clinical efficacy between treatment group and control group were included in the Meta-analysis, the result showed that treatment group had a significant clinical efficacy than control group(RR:1.26,95%CI:1.22-1.30,P<0.0001).A total of 6 studies about the improvement of the pure tone average(PTA)in the two groups were included in the Meta-analysis, the PTA gain was significant better in hyperbaric oxygenation group(WMD:11.8,95%CI:4.77-18.83,P<0.000 1).A total of 11 studies about the stage of using hyperbaric oxygenation therapy were included in the Meta-analysis, the result suggested that the early use of hyperbaric oxygenation therapy had better effect than the late use of hyperbaric oxygenation (RR:1.42,95%CI:1.31-1.53,P<0.000 01).Conclusion:The clinical efficacy of hyperbaric oxygenation combined with drug therapy is better than drug therapy alone, the PTA gain is significantly improved and the introduction of hyperbaric oxygenation therapy at the earlier stage shows better results.
8.Survey of GPI-PLD Gene Polymorphisms in Healthy Persons and Patients With Systemic Lupus Erythematosus
Hong YU ; Jianhua TANG ; Yidan WANG
Journal of Chinese Physician 2001;0(06):-
Objective To analyze the polymorphisms of glycosylphosphatidylinositol-specific phospholipase D (GPI-PLD) gene Exon1 and Exon25,GPI-PLD activity of leucocyte in peripheral blood and their relationship in systemic lupus erythematosus patients of Han nationality in Hunan Chinese.Methods The polymorphisms were analyzed by PCR-SSCP and sequencing. GPI-PLD levels were determined by using glycosylphosphatidylinositol (GPI) anchored placental alkaline phosphatase (PLAP) as substrate and triton-X114 partioning.Results There were fourteen variations in the coverage of GPI-PLD gene Exon 1 of both 109 healthy persons' and 62 systemic lupus erythematosus patients',including seven variations at transcriptional start site upstream and seven variations at Exon1. The codons of variation were 14TTG→AAG (Leu14Lys),17CTC→GTC (Leu17Val),20AGA→AAA (Arg20Lys),21GGT→GGG (Gly21Gly),30GTA→ATA (Val30Ile),which leaded to four missense mutations and one synonymous mutation. In addition, the frequency of the variation at transcriptional start site upstream -24 C→T was significantly different between healthy control and systemic lupus erythematosus patients. At meanwhile, there was a variation in Exon25, the +60496 G→A, between two groups. The total various frequency, which was determined by SSCP, of healthy person was 33 03 percent and systemic lupus erythematosus patient was 25 81 percent. On the basis of the percentage of GPI-anchored PLAP conversion, the leucocyte GPI-PLD activities of total 62 systemic lupus erythematosus patients were measured. As compared with 109 healthy persons as control group, the leukocyte GPI-PLD activities of systemic lupus erythematosus patients were significantly raised, but GPI-PLD activities were not correlated with polymorphism sites significantly.Conclusions The leukocyte GPI-PLD gene in peripheral blood, which belongs to healthy persons and systemic lupus erythematosus patients of Han mationality in Hunan Chinses,is polymorphism.The frequency of transcriptional start site upstream -24 is significantly different between healthy control and systemic lupus erythematosus patients.The leukocyte GPI-PLD activeties of patients' also significantly increase.
9.A randomized controlled trial of the efficacy of combination of gemcitabine and carboplatin or paclitaxel and combination of paclitaxel and carboplatin in the treatment for advanced non-small cell lung cancer.
Qing GAO ; Fu-yuan WANG ; Hong YU
Chinese Journal of Oncology 2011;33(11):874-876
Adult
;
Aged
;
Aged, 80 and over
;
Anemia
;
chemically induced
;
Antineoplastic Combined Chemotherapy Protocols
;
adverse effects
;
therapeutic use
;
Carboplatin
;
administration & dosage
;
Carcinoma, Non-Small-Cell Lung
;
drug therapy
;
pathology
;
Deoxycytidine
;
administration & dosage
;
analogs & derivatives
;
Female
;
Follow-Up Studies
;
Humans
;
Leukopenia
;
chemically induced
;
Lung Neoplasms
;
drug therapy
;
pathology
;
Male
;
Middle Aged
;
Neoplasm Staging
;
Paclitaxel
;
administration & dosage
;
Remission Induction
;
Survival Rate
;
Thrombocytopenia
;
chemically induced
10.Development of a New Multi-Purpose Face Mask for Oxygen Provision in First Aid
Jiaming CAO ; Hong YU ; Xianghe WANG
Chinese Medical Equipment Journal 2003;0(10):-
Objective To develop a new multi-purpose face mask for oxygen provision in first aid,which can be used in both war time and peace time.Methods The structure,operating principle and application of a multi-purpose face mask,whose transparent silicone mask body has even the entrance of nested endoscopy and oxygen concentration regulating twist,are introduced in this paper.Results This mask can be used in painless endoscopy and emergent oxygen supply in tracheal intubatton.Conclusion The mask can greatly enhance the safety of painless endoscopy and it can also be used as mask for the use of general anesthesia.